Amylyx Pharmaceuticals (AMLX) Non Operating Income (2021 - 2026)

Amylyx Pharmaceuticals' Non Operating Income history runs 6 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 31.59% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $9.2 million, a 15.67% decrease from a year earlier, with the FY2025 full-year figure at $8.6 million, down 31.7% from the prior year.
• Non Operating Income eased to $2.5 million in Q1 2026 per AMLX's latest filing, from $3.7 million in the prior quarter.
• Across five years, Non Operating Income topped out at $4.5 million in Q4 2023 and bottomed at $112000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $2.5 million (2026), against an average of $2.5 million.
• Across the five-year window, Non Operating Income jumped 8610.34% in 2022 and slumped 60.57% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $2.5 million in 2022, then surged by 84.04% to $4.5 million in 2023, then sank by 45.55% to $2.5 million in 2024, then soared by 47.67% to $3.7 million in 2025, then plunged by 31.68% to $2.5 million in 2026.
• Per Business Quant, the three latest AMLX Non Operating Income figures stand at $2.5 million (Q1 2026), $3.7 million (Q4 2025), and $1.6 million (Q3 2025).